85 / 89
85
oral melphalan/prednisone in patients with multiple
myeloma not eligible for transplantation: results of a
randomized trial from the Turkish Myeloma Study
Group. Eur J Haematol 2011;86:16-22.
58.
San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA,
Shpilberg O, Kropff M, et al. Bortezomib plus melphalan
and prednisone for initial treatment of multiple myeloma.
N Engl J Med 2008;359:906-17.
59.
Dimopoulos MA, Mateos MV, Richardson PG, Schlag R,
Khuageva NK, Shpilberg O, et al. Risk factors for, and
reversibility of, peripheral neuropathy associated with
bortezomib-melphalan-prednisone in newly diagnosed
patients with multiple myeloma: subanalysis of the phase
3 VISTA study. Eur J Haematol 2011;86:23-31.
60.
Mateos MV, Richardson PG, Schlag R, Khuageva NK,
Dimopoulos MA, Shpilberg O, et al. Bortezomib plus
melphalan and prednisone compared with melphalan
and prednisone in previously untreated multiple
myeloma: updated follow-up and impact of subsequent
therapy in the phase III VISTA trial. J Clin Oncol
2010;28:2259-66.
61.
Dimopoulos MA, Richardson PG, Schlag R, Khuageva
NK, Shpilberg O, Kastritis E, et al. VMP (Bortezomib,
Melphalan, and Prednisone) is active and well tolerated in
newly diagnosed patients with multiple myeloma with
moderately impaired renal function, and results in
reversal of renal impairment: cohort analysis of the phase
III VISTA study. J Clin Oncol 2009;27:6086-93.
62.
Harousseau JL, Palumbo A, Richardson PG, Schlag R,
Dimopoulos MA, Shpilberg O, et al. Superior outcomes
associated with complete response in newly diagnosed
multiple myeloma patients treated with nonintensive
therapy: analysis of the phase 3 VISTA study of